



Case report

Unusual carbapenem resistant but ceftriaxone and cefepime susceptible *Klebsiella oxytoca* isolated from a blood culture: Case report and whole-genome sequencing investigation

Shangxin Yang^{a,b,*}, Peera Hemarajata^c, Laura Shevy^d, Mario Maciariello^b, Karissa Culbreath^{a,b}, Karen Bush^e, Romney Humphries^c

^a University of New Mexico, Department of Pathology, Albuquerque, NM, United States

^b TriCore Reference Laboratories, Albuquerque, NM, United States

^c University of California Los Angeles, Department of Pathology and Laboratory Medicine, Los Angeles, CA, United States

^d University of New Mexico Hospital, Department of Infectious Diseases, Albuquerque, NM, United States

^e Indiana University, Department of Molecular and Cellular Biochemistry, United States



ARTICLE INFO

Keywords:

Carbapenem resistance
Klebsiella oxytoca
 bla_{OXY}
 Porin mutation
 Efflux system
 Whole-genome sequencing

ABSTRACT

A carbapenem resistant but ceftriaxone and cefepime susceptible *Klebsiella oxytoca* was isolated from the blood of a patient with polymicrobial bacteremia after 2 weeks of ertapenem treatment. Whole-genome sequencing identified no carbapenemase gene nor plasmid, but only bla_{OXY-2.8} gene with a mutation in the promoter that's been reported to increase its expression. Two other specific carbapenem resistance mechanisms including mutated porin genes and the AcrAB-TolC efflux system genes were also identified. Clinicians need to be aware of such unusual antibiogram and should not assume carbapenems are always broader spectrum antibiotics than expanded-spectrum cephalosporins.

Introduction

Klebsiella oxytoca is associated with blood stream, intra-abdominal and urinary tract infections. The rise of carbapenem resistant *Klebsiella oxytoca* (CRKO) has become part of the urgent threat of carbapenem resistant Enterobacteriaceae (CRE) epidemic, and most CRKO carry plasmid-mediated carbapenemase genes that are highly transmissible [1–4]. Here we report a case of bacteremia with an unusual CRKO that is susceptible to ceftriaxone and cefepime.

Case report

A patient with history of recent tricuspid valve endocarditis with septic pulmonary emboli, as well as a large, obstructing staghorn calculus developed polymicrobial bacteremia including *Escherichia coli* and ESBL *Klebsiella pneumoniae* five days after suffering an iatrogenic ureteral perforation during a failed percutaneous nephrolithotomy (day 0). Empiric vancomycin and piperacillin-tazobactam were initiated and changed to ertapenem monotherapy when blood culture identification and susceptibilities were available. Subsequent blood cultures grew vancomycin resistant *Enterococcus faecium* (days 11, 13), which

prompted addition of daptomycin. After 2 weeks of ertapenem, the patient continued to be clinically septic, and ertapenem was switched to meropenem to broaden coverage. Three days after changing to meropenem (day 25), blood cultures grew CRKO, *Stenotrophomonas maltophilia*, and *Enterococcus faecalis*. Amikacin was added to cover the CRKO, trimethoprim-sulfamethoxazole was started for the *Stenotrophomonas maltophilia*, and daptomycin and meropenem were continued. The CRKO isolate had an unusual antibiogram (Table 1), as it was resistant to cefazolin, piperacillin/tazobactam, ertapenem and meropenem, and intermediate to imipenem but susceptible to aztreonam and most 3rd and 4th generation cephalosporins including ceftriaxone, ceftazidime, and cefepime except cefotaxime (resistant) and ceftolozane/tazobactam (intermediate). It was susceptible to ceftazidime/avibactam. Due to this susceptibility pattern, meropenem was switched to cefepime on day 29, after which no *Enterobacteriaceae* has been isolated to date. The patient didn't have recent travel history.

Investigation

To investigate the carbapenem resistance mechanism of this CRKO isolate, the modified carbapenem inactivation method (CIM) [5] and

* Corresponding author at: 1001 Woodward PL NE, Albuquerque, NM 87102, United States.
 E-mail address: shyang@salud.unm.edu (S. Yang).

Table 1
Drug Susceptibility Results of CRKO (MIC = minimal inhibitory concentration).

Drugs	Susceptibility Results	Test Methods
Amikacin	MIC < = 8 Susceptible	BD Phoenix™ Automated System
Ampicillin	MIC > 16 Resistant	BD Phoenix™ Automated System
Aztreonam	MIC < = 2 Susceptible	BD Phoenix™ Automated System
Ampicillin/Sulbactam	MIC > 16/8 Resistant	BD Phoenix™ Automated System
Cefepime	MIC = 2 Susceptible	BD Phoenix™ Automated System
Cefepime	MIC = 2 Susceptible	Manual Broth Microdilution
Cefoxitin	MIC > 16 Resistant	BD Phoenix™ Automated System
Ciprofloxacin	MIC > 2 Resistant	BD Phoenix™ Automated System
Ceftriaxone	MIC < = 1 Susceptible	BD Phoenix™ Automated System
Ceftriaxone	MIC = 1 Susceptible	Manual Broth Microdilution
Ceftolozane/Tazobactam	MIC = 4/4 Intermediate	Manual Broth Microdilution
Cefotaxime	Zone size = 20 Resistant	Manual Disk Diffusion
Ceftazidime	MIC = 2 Susceptible	Manual Broth Microdilution
Ceftazidime/avibactam	MIC < = 2 Susceptible	Manual Broth Microdilution
Cefazolin	MIC > 16 Resistant	BD Phoenix™ Automated System
Cefazolin	MIC > 32 Resistant	Manual Broth Microdilution
Colistin	MIC < = 2 Susceptible	Manual Broth Microdilution
Ertapenem	MIC > 2 Resistant	BD Phoenix™ Automated System
Ertapenem	MIC > 4 Resistant	Manual Broth Microdilution
ESBL	Negative	BD Phoenix™ Automated System
Gentamicin	MIC < = 2 Susceptible	BD Phoenix™ Automated System
Imipenem	MIC = 2 Intermediate	Manual Broth Microdilution
Meropenem	MIC > 8 Resistant	BD Phoenix™ Automated System
Meropenem	MIC = 4 Resistant	Manual Broth Microdilution
Piperacillin/Tazo	MIC > 64/4 Resistant	BD Phoenix™ Automated System
Piperacillin/Tazo	MIC > 64/4 Resistant	Manual Broth Microdilution
Sulfameth/trimeth	MIC > 2/38 Resistant	BD Phoenix™ Automated System
Tetracycline	MIC = 8 Intermediate	BD Phoenix™ Automated System

the modified Hodge test (MHT) [5] were performed and both were negative. Additionally, the isolate was negative for carbapenemase genes using the Cepheid GeneXpert CARBA-R (for KPC, NDM, IMP, VIM, OXA-48) and a laboratory developed real-time PCR (for KPC, NDM, IMP, VIM, SME, OXA-48) [6]. To further characterize the molecular mechanism of resistance, whole-genome sequencing (WGS) was performed using Illumina MiSeq system [7] and the WGS data was deposited to NCBI (accession # PCMV01000000). Analysis using PlasmidFinder [8] suggested that the isolate did not harbor a plasmid. The only β -lactamase gene identified by the WGS using ResFinder [9] was a chromosomally encoded *bla*_{OXY-2-8} gene with a GATA[G → A]T mutation in the –10 box of its promoter, which has been reported to cause overexpression of the gene and > 100 fold increase in enzyme activity [10]. Compared to the originally reported *bla*_{OXY-2-8} gene, there are four single-nucleotide polymorphisms (SNPs) resulting in amino acid substitutions S23G, D38A, N134T, and A239T. Several reports have shown residual carbapenemase activities of chromosomal OXY-2 enzymes including K1 [11–14] that may also have ESBL-like properties [14]. The *bla*_{OXY-2-8} gene was only recently identified (NCBI Reference Sequence: NG_049857.1) and the characteristics of this new enzyme is unknown. More studies are undergoing to verify the residual carbapenemase activities of the OXY-2-8 enzyme in this isolate.

WGS also identified genes involved in the AcrAB-TolC efflux system including *acrA*, *acrB*, *tolC* [15] and their regulatory genes including *acrR*, *ramA*, *marA*, *robA*, *msbA*, and *soxR*, etc [16,17]. Interestingly, we identified SNPs in the *acrR* gene (Y114F and V165I) associated with increased AcrAB expression in *K. pneumoniae* [18]. We also found numerous missense mutations in the porin genes *ompK35* and *ompK36* compared to the wild type genes, apparently leading to nonfunctional porins, which had been associated with carbapenem resistance [15,19].

Discussion

Currently, most reported CRKO contain plasmids carrying carbapenemase [1–4] or ESBL genes [20]. To our knowledge, this is the first report of CRKO without a plasmid, or carbapenemase or non-OXY-related ESBL genes. Overexpression of both *bla*_{OXY-2-8} and the AcrAB-TolC

efflux system, as well as loss of function in key porins, most likely contributed to carbapenem resistance in this isolate. The unusual antibiogram of this isolate (i.e. resistant to carbapenems but susceptible to cefepime and ceftriaxone) led to the change of treatment regimen from meropenem to cefepime, which treated the CRKO blood stream infections. Clinicians need to be aware of such an unusual CRE, as more plasmid- and carbapenemase-free CRE may be on the horizon. Despite their reputations in general clinical medicine, carbapenems may not always be broader spectrum antibiotics than expanded-spectrum cephalosporins.

Disclosure

The authors declare that they have no competing interests.

Acknowledgement

Not applicable.

References

- [1] Yigit H, Queenan AM, Rasheed JK, Biddle JW, Domenech-Sanchez A, Alberti S, et al. Carbapenem-resistant strain of *Klebsiella oxytoca* harboring carbapenem-hydrolyzing beta-lactamase KPC-2. *Antimicrob Agents Chemother* 2003;47(December (12)):3881–9.
- [2] Vergara-López S, Domínguez MC, Conejo MC, Pascual Á, Rodríguez-Baño J. Lessons from an outbreak of metallo- β -lactamase-producing *Klebsiella oxytoca* in an intensive care unit: the importance of time at risk and combination therapy. *J Hosp Infect* 2015;89(February (2)):123–31.
- [3] Caltagirone M, Bitar I, Piazza A, Spalla M, Nucleo E, Navarra A, et al. Detection of an IncA/C plasmid encoding VIM-4 and CMY-4 β -lactamases in *Klebsiella oxytoca* and *Citrobacter koseri* from an inpatient in a cardiac rehabilitation unit. *New Microbiol* 2015;38(July (3)):387–92.
- [4] Jamal W, Rotimi VO, Albert MJ, Khodakhast F, Nordmann P, Poirel L. High prevalence of VIM-4 and NDM-1 metallo- β -lactamase among carbapenem-resistant Enterobacteriaceae. *J Med Microbiol* 2013;62(August (Pt 8)):1239–44.
- [5] Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-seventh informational supplement; M100-S26. CLSI; 2017.
- [6] Pollett S, Miller S, Hindler J, Usulan D, Carvalho M, Humphries RM. Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health

- care system in Los Angeles, California, from 2011 to 2013. *J Clin Microbiol* 2014;52(November (11)):4003–9.
- [7] Yang S, Hemarajata P, Hindler J, Ward K, Adisetiyo H, Li F, et al. Investigation of a suspected nosocomial transmission of blaKPC3-mediated carbapenem-resistant *Klebsiella pneumoniae* by whole genome sequencing. *Diagn Microbiol Infect Dis* 2016;84(April (4)):337–42.
- [8] Carattoli A, Zankari E, Garcia-Fernandez A, VoldbyLarsen M, Lund O, Villa L, et al. PlasmidFinder and pMLST: in silico detection and typing of plasmids. *Antimicrob. Agents Chemother* 2014(April (28th)).
- [9] Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother* 2012(July (10)).
- [10] Fournier B, Lagrange PH, Philippon A. beta-lactamase gene promoters of 71 clinical strains of *Klebsiella oxytoca*. *Antimicrob Agents Chemother* 1996;40(February (2)):460–3.
- [11] Queenan AM, Shang W, Flamm R, Bush K. Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. *Antimicrob Agents Chemother* 2010;54(January (1)):565–9.
- [12] Granier SA, Leflon-Guibout V, Goldstein FW, Nicolas-Chanoine MH. New *Klebsiella oxytoca* beta-lactamase genes bla(OXY-3) and bla(OXY-4) and a third genetic group of *K oxytoca* based on bla(OXY-3). *Antimicrob Agents Chemother* 2003;47(September (9)):2922–8.
- [13] Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. Prevalence of β -lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U. S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). *Antimicrob Agents Chemother* 2013;57(July (7)):3012–20.
- [14] Granier SA, Leflon-Guibout V, Nicolas-Chanoine MH, Bush K, Goldstein FW. The extended-spectrum K1 beta-lactamase from *Klebsiella oxytoca* SC 10,436 is a member of the bla(OXY-2) family of chromosomal *Klebsiella* enzymes. *Antimicrob Agents Chemother* 2002;46(June (6)):2056–7.
- [15] Fenosa A, Fusté E, Ruiz L, Veiga-Crespo P, Vinuesa T, Guallar V, et al. Role of TolC in *Klebsiella oxytoca* resistance to antibiotics. *J Antimicrob Chemother* 2009;63(April (4)):668–74.
- [16] Padilla E, Llobet E, Doménech-Sánchez A, Martínez-Martínez L, Bengoechea JA, Albertí S. *Klebsiella pneumoniae* AcrAB efflux pump contributes to antimicrobial resistance and virulence. *Antimicrob Agents Chemother* 2010;54(January (1)):177–83.
- [17] Bialek-Davenet S, Marcon E, Leflon-Guibout V, Lavigne JP, Bert F, Moreau R, et al. In vitro selection of ramR and soxR mutants overexpressing efflux systems by fluoroquinolones as well as ceftoxitin in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2011;55(June (6)):2795–802.
- [18] Sheng ZK, Hu F, Wang W, Guo Q, Chen Z, Xu X, et al. Mechanisms of tigecycline resistance among *Klebsiella pneumoniae* clinical isolates. *Antimicrob Agents Chemother* 2014;58(November (11)):6982–5.
- [19] Chen LR, Zhou HW, Cai JC, Zhang R, Chen GX. Combination of IMP-4 metallo-beta-lactamase production and porin deficiency causes carbapenem resistance in a *Klebsiella oxytoca* clinical isolate. *Diagn Microbiol Infect Dis* 2009;65(October (2)):163–7.
- [20] Sheng WH, Badal RE, Hsueh PR. SMART Program. Distribution of extended-spectrum β -lactamases, AmpC β -lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). *Antimicrob Agents Chemother* 2013;57(July (7)):2981–8.